(density,2)
(fruit,,1)
(compared;,1)
(symptoms.,3)
(phthalates,1)
(57.5-96.2%,1)
(Quercus,3)
(population.To,1)
(include,1)
(been,9)
(reactions.,2)
(Kazakhstan,,1)
(advice,1)
(challenges,2)
(total,,1)
(asthma-related,1)
(over,8)
(improved,1)
(perennial,3)
((tree:,3)
(any,2)
(exposure.Green,1)
(treatment.We,1)
(November.,1)
(pharmacotherapy,1)
(amount,3)
((SmSEA),1)
(need.,2)
(pathogenesis-related,1)
(TGF-β,1)
(rapid,1)
((odds,1)
(statistically,5)
(allergen-based,1)
(hoc,1)
(are,20)
(EudraCT,2)
(efficacy,7)
(sites,1)
(2.,1)
(221),,1)
(mild,2)
(diary;,1)
(mediators,1)
(monitoring,1)
(Treatment,1)
(Phl,2)
((EudraCT,1)
(Immunotherapy,1)
(administration.,2)
(our,2)
(contributors,1)
(randomly,1)
(cetirizine,,1)
(26,455,1)
(identity.,1)
(aid,1)
(IL-17,2)
(form,2)
((two,1)
(distinct,2)
(infections,1)
(environments,1)
(SLIT-tablets,6)
(rule,,1)
(recently,1)
(induced,7)
(SAR.This,1)
(exposures,4)
(comprehensive,1)
(After,1)
(IPSE/alpha-1,,1)
(confirm,1)
(ambient,2)
(1-week,1)
(proteins,1)
((P,1)
(total,12)
(sources,2)
(serum,2)
((25.3%),,1)
(new,2)
(44,1)
(Ethics,1)
(conflicting,1)
("allergy,",1)
(treatment,27)
(potency,1)
(IL-35,1)
(suggest,4)
(palo,1)
(SAR,2)
(T,2)
(magnitude,1)
(severe,4)
((LAR),1)
(gold,1)
(area-level,1)
(trial.,2)
((TGP),1)
(animal,4)
(nuts.,2)
(4,,1)
(counts,,1)
(Recently,,1)
(rAmb,1)
(oral/pharyngeal,1)
(point,2)
(low,7)
(cornerstone,1)
(Health,1)
((~ 560 ppm),,1)
(participants,4)
(oak.A,1)
(couple,1)
(proliferation,1)
(concentrations.,2)
(foreign,1)
(single,1)
(grains,1)
(AIT,3)
(asthma.,4)
(assess,1)
(inconclusive,,1)
(advice,,1)
(rate,2)
(Clinic,1)
(placebo,14)
(developed,3)
((ie,,1)
(change,,2)
(Suwon,,1)
(first,5)
((AR),2)
((OAS),,1)
(without,7)
(just,1)
(raised,1)
("oral,1)
(analysis,3)
(pollinosis.,1)
(deduced,1)
(raw,2)
(shares,1)
(test.,2)
((tree/grass),1)
(relationship,2)
(Therefore,,1)
(0.124),1)
(meaningful,1)
(rhinitis,,4)
(how,1)
(emphasis,1)
(disintegrating,1)
(nonregional,1)
(into,1)
(extreme,1)
(implicated,2)
(Regular,1)
(Previously,,1)
(serology,3)
(helminths,1)
(allergy,24)
(Further,2)
(fever,1)
(testing,,1)
(Tucson,,1)
((NSS).In,1)
(ELISA,3)
((BPS),1)
(allergies.,3)
((Allergon,1)
(UK.,1)
(4,5)
(conjunctivitis,2)
(subgroups,1)
(likelihood,1)
(world.,2)
(1-Cha,1)
(species,3)
(molecular,2)
(dander,,1)
(emerging,1)
(tablet.,1)
(post,1)
(assay.A,1)
(Report,1)
(provocation,3)
(disease,2)
(duration,1)
(other,3)
(Allergenic,1)
(molecule-based,5)
(nonallergic,1)
(applying,1)
(weight,1)
(further,1)
(verde,1)
(upcoming,2)
("treatment."Oral,1)
(maximum,1)
(counts,1)
(remain,1)
(discuss,1)
(questionnaires,1)
(considered,4)
(electronic,2)
(allergenic,4)
(allowed,1)
(between,12)
(clinic,1)
(hypothesis,,1)
(conditions,,1)
(grasses,,1)
(patient.The,1)
((0.2%),1)
(aeroallergens,4)
(region,,1)
(sIgE ≥ 15 KU/L,1)
(Total,1)
(revealed,1)
(Uppsala,,1)
(antiserum.,1)
(Arizona,,1)
(1),1)
(commonly,2)
(predominantly,1)
(genera,1)
(included,7)
(conjunctivitis,,1)
(under,3)
(Birch,1)
(health,2)
(its,3)
(previously,1)
(hay,1)
((HDM),,1)
(produced,2)
(have,14)
(highest,5)
(several,1)
(affected,1)
(dander,1)
(testing,5)
(ecological,1)
((48%),,1)
(TGF-β,,1)
(Our,1)
(qualified,2)
(varying,1)
(cDNA,1)
((p,7)
(mitigate,1)
(Here,1)
(relationship,,1)
(p,11)
(presents,1)
(peaks,2)
(19-61,1)
(pharmacotherapy,,1)
(history,2)
(prevent,1)
(self-administered,1)
(sIgE,1)
(disorder,,1)
(multiple,1)
(experimental,1)
(years.,1)
((Quercus,1)
(induce,1)
(better,1)
((ASIT),1)
(cetirizine,5)
(22.4%;,1)
(aimed,2)
(showed,6)
(1,112.30,1)
(acutissima),1)
(residential,2)
(receiving,1)
(SIT.,1)
(Its,1)
(level,2)
(plants,1)
(acute,1)
(U.S.,1)
(pruritus,,3)
(patients.,2)
(using,10)
(measured.,1)
(Conjunctivitis,1)
((total,1)
(they,1)
(likely,1)
(subject,1)
(birch,7)
(information,,1)
(tolerability,3)
(due,4)
(respectively).,1)
(Tucson,1)
(Pollen,4)
(ages,2)
(after,9)
(clinically,3)
(Europe.,1)
(Translational,1)
(facilitate,1)
(prospective,,1)
(well-known,1)
(30-day,2)
(panel,2)
(suffers,1)
(exposed,1)
(coupled,1)
(areas.,1)
(tongue,1)
(avoidance,2)
(matured,1)
(SLIT,9)
(throat,2)
(II,1)
(guidelines.Skin,1)
(supports,1)
(1299%,,1)
(mass,1)
((Gramineae),1)
(observed,2)
(starting,1)
(-2.1,1)
(rhinitis,11)
(term,1)
(IL-17,,1)
(There,1)
(pollen,,7)
(mild-moderate,1)
("PFAS,",1)
(P,2)
(locally,1)
(Regulatory,1)
(119),1)
(only,6)
((DU),,1)
(complex,1)
(house,3)
(normally,1)
(still,1)
(2013,1)
((ALK,,1)
(IL-35,,1)
((CCDs).,1)
(pollen,64)
(2015.,1)
(developments,1)
(reductions,3)
(1.23-5.39];,1)
(addition,,1)
(typical,2)
(treating,1)
(can,10)
(one-third,1)
(general,,1)
({CI},,1)
(discovered,1)
(rhinoconjunctivitis,8)
((OAS).We,1)
(duration,,1)
(0.03),,1)
(disease,,2)
(none,1)
(re-training,1)
(life,,1)
(immunotherapy,14)
(delivery,1)
(tolerated,,3)
(Seoul,2)
(<,4)
(Arizona,1)
(Bermuda,1)
(mild,,2)
(Panel,1)
(rated,1)
(amplify,1)
(review,4)
(ingestion,1)
(Korea.,2)
(allergy,,1)
(distribution,1)
(interpreted,1)
(grass:,3)
(Childhood,1)
(plants,,1)
(1.A,1)
(0.230),1)
(targeted,1)
(Allergy,2)
(e.g.,,1)
(groups,7)
(life,3)
(importance,1)
(significantly,12)
(vegetables.,1)
(followed,2)
(continues,1)
(expression,2)
(Ambrosia,2)
(expected,2)
(identify,3)
(AC.,1)
(merged,1)
(change,2)
(throat,,1)
(ragweed-pollen,,1)
(3-specific,1)
(among,2)
(two,4)
(tomatoes,,1)
(Asian,1)
(Science,1)
(extracts.,1)
(subtropical,1)
(Korean,2)
(adequate,1)
(Participants,1)
(mostly,1)
(performed,2)
(Meta-analyses,1)
(demonstrated,3)
(novel,2)
(Cha,9)
(dominant,2)
(frequency,1)
(attached,1)
(0.032/r,1)
(subject's,1)
(action.,1)
(approach,1)
(polyethylene,1)
(so,1)
((-2.1,1)
(0.006).Regional,1)
(underwent,3)
(extracted,1)
